February 19, 2013
In the following video, Motley Fool health care bureau chief Brenton Flynn continues his look at Intuitive Surgical's (NASDAQ: ISRG ) annual report. Specifically, he takes a look at one possible new competitive threat emerging on the company's radar. The company, called IMRIS, has its primary focus on intraoperative MRI technology, but is currently conducting clinical trials for a surgical platform targeting neurological conditions. Brenton tells investors whether this company is a concern and what other competitive threats Intuitive might be facing.
Are stories of Intuitive's demise greatly exaggerated?
Recently, some investors have questioned Intuitive Surgical's future. However, Intuitive Surgical expert Karl Thiel believes a visible path to long-term growth persists. Will Intuitive capitalize, or be crushed by unforeseen pitfalls? His report highlights all of the key opportunities and risks facing the company -- and includes a full year of ongoing updates as key new hits -- so be sure to claim your copy by clicking here now.